James A. Mish

22nd Century Group, Inc. (NASDAQ: XXII) announced that John Miller, who leads the tobacco business unit, has been appointed as interim CEO. James A. Mish, who has served as CEO since June 2020, will continue to serve as a member of the board of directors. The company has secured an additional $11.7...

22nd Century Group, Inc. (NASDAQ: XXII) has entered into definitive agreements with certain investors for the purchase and sale of 778,634 shares of common stock and warrants at a price of $3.80 per share in a registered direct offering priced above market. Gross proceeds to the company from the...

22nd Century Group, Inc. (NASDAQ: XXII) released results for the first quarter ended March 31, 2023, revealing net revenues of $22.0 million, an increase of 142.8% from the same period in 2022. Q1 2023 Financial Results Revenue from hemp/cannabis-related products was $13.0 million, compared to $0...

22nd Century Group, Inc. (NASDAQ: XXII) announced a new three-year exclusive license and distribution agreement with Cookies. “This transformational strategic license, manufacturing and distribution agreement with Cookies establishes the foundation of an innovative new CDMO plus distribution...

22nd Century Group, Inc. (NASDAQ: XXII) net revenue for the Q4 2022 was $19.2 million, an increase of 141.3% from $8 million in Q4 2021. Q4 2022 Financial Highlights Gross loss was $646,000, an unfavorable decrease of 379.7% compared to gross profit of $231,000 in the prior year period. Net...

22nd Century Group, Inc. (NASDAQ: XXII) announced a new $21 million senior secured debenture financing to support increased working capital needs related to the significant growth outlook in both its VLN and GVB business lines. The new three-year financing was issued at 5% original issuance...

22nd Century Group, Inc. (NASDAQ: XXII) announced the acquisition of privately held RX Pharmatech Ltd, a United Kingdom distributor of cannabinoids with 1,276 novel food applications with the U.K. Food Standards Agency (FSA). Terms of the agreement include an up-front payment of $650,000 in cash...

GVB Biopharma, a 22nd Century Group company (NASDAQ: XXII) has opened a new, strategically-located distribution facility in the Netherlands to support its growing business in Europe, the Middle East, and Africa. The new distribution facility will increase existing and new customer access to GVB...

22nd Century Group, Inc. (NASDAQ: XXII) net revenues for the third quarter of 2022 were $19.4 million, an increase of 148.2% from 2021. The increase was due to increased contract manufacturing volumes as well as the addition of GVB Biopharma revenue for the full third quarter. Q3 2022 Financial...

22nd Century Group, Inc. (NASDAQ: XXII) announced the acquisition of privately held GVB Biopharma. GVB - a contract development and manufacturing organization - provides hemp-derived active ingredients for the pharmaceutical and consumer goods industries worldwide. Deal Details The aggregate...

22nd Century Group, Inc. (NASDAQ: XXII) reported results for the first quarter ended March 31, 2022.. The company will host a live audio webcast on May 5, at 10:00 a.m. ET. First Quarter 2022 Financial Results Net loss was $8.9 million, representing a net loss per share of $(0.05), comparing to...

22nd Century Group, Inc. (NASDAQ:XXII) received notification from the Office of the Illinois Attorney General's Tobacco Enforcement Bureau that its VLN cigarettes will be listed in the Illinois Directory of Participating Manufacturers effective April 4, 2022. Registration permits the company to...

22nd Century Group, Inc. (NASDAQ: XXII), and its global plant research partner KeyGene achieved a breakthrough in their research leading to the successful transformation of the hemp/cannabis plant genome using proprietary plant transformation, regeneration technology and clear...

22nd Century Group, Inc. (NASDAQ: XXII) announced that it will host a live webcast on Tuesday, March 1, 2022, at 10:00 AM ET to discuss its 2021 fourth quarter and full year results. The company will report its fourth quarter and full year 2021 results in a press release at 6:00 AM ET the same day...

Canadian marijuana titan Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:ACB) together with 22nd Century Group, Inc. (NASDAQ: XXII) will license biosynthesis intellectual property to Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON). The licensed intellectual property is designed to help advance the research...